Moffitt Cancer Center Supports Personalized Medicine with Oracle Health Sciences Technology

Moffitt Cancer Center has gone live with its next-generation health and research informatics (HRI) platform, built on Oracle Health Sciences solutions. In early deployment, the new platform enables Moffitt to accelerate clinical trial patient recruitment and advance personalized medicine.

The new informatics environment, built using Oracle Health Sciences Enterprise Healthcare Analytics, Oracle Healthcare Master Person Index, Oracle Fusion Middleware, and Oracle Database 11g, supports Moffitt’s Total Cancer Care™ program by generating new intelligence from existing systems.

Securely synthesizing data from numerous clinical sources, a state-of-the-art biobank, and patient-reported information, the Oracle solution delivers rapid and accurate analysis that is helping to reveal new insight around treatment effectiveness at an individual level, with the goal of advancing personalized medicine initiatives.

Since deploying the solution, Moffitt has experienced an increase in the number of data requests from researchers and has streamlined patient cohort identification for cancer treatment studies.

“Oracle is honored to play a foundational role in Moffitt Cancer Center’s new health and research informatics platform,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences. “Even in its early deployment, the platform shows tremendous potential to help Moffitt Cancer Center advance its personalized medicine initiative and improve outcomes. Moffitt’s work in this area is a testament to the power of IT to drive innovation in healthcare.”

Moffitt has automated clinical trial candidate identification, eliminating a manualeffort that required months of reviewing paper and electronic data sources to identify the best candidates. Today, researchers can access information on-demand, from their desktops to find de-identified patient cohorts withinminutes. Increasing the volume of data available for analysis will enable Moffitt to identify and validate targeted patient populations for cancer trials and, thereby, improve clinical trial efficiency and productivity.

Data collected electronically at the point-of-care can be made available for advanced research studies. Discoveries from this research will ultimately be reincorporated into clinical decision support tools that facilitate the delivery of individualized and personalized patient care.